Terutroban
Encyclopedia
Terutroban is an antiplatelet agent developed by Servier Laboratories
. , it is being tested for the secondary prevention of acute thrombotic complications in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack).
. It blocks thromboxane induced platelet aggregation and vasoconstriction
.
Servier Laboratories
Servier Laboratories is a privately owned French pharmaceutical company that specialises in medication for cardiological and rheumatological conditions, as well as for diabetes and clinical depression. The consolidated turnover for the 2005/2006 financial year was €3.5 billion...
. , it is being tested for the secondary prevention of acute thrombotic complications in the Phase III clinical trial PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack).
Method of action
Terutroban is a selective antagonist of the thromboxane receptorThromboxane receptor
The thromboxane receptor is a protein on the surface of cells in the endothelium of blood vessels and in the placenta which interacts with the eicosanoid lipid thromboxane. It is a G-protein coupled receptor coupled to the G protein Gq.-Gene:...
. It blocks thromboxane induced platelet aggregation and vasoconstriction
Vasoconstriction
Vasoconstriction is the narrowing of the blood vessels resulting from contraction of the muscular wall of the vessels, particularly the large arteries, small arterioles and veins. The process is the opposite of vasodilation, the widening of blood vessels. The process is particularly important in...
.